Rgenta
Rgenta develops RNA-based therapeutics for neurological disorders, oncology, and other diseases. The company builds compound libraries designed to recognize RNA target sites and modulate their function, particularly those mediated by regulatory proteins. Its data-driven mRNA target identification platform accounts for cell type-specific target regulation and predicts the biological consequences of target modulation,…
Funding snapshot
About
Rgenta develops RNA-based therapeutics for neurological disorders, oncology, and other diseases. The company builds compound libraries designed to recognize RNA target sites and modulate their function, particularly those mediated by regulatory proteins. Its data-driven mRNA target identification platform accounts for cell type-specific target regulation and predicts the biological consequences of target modulation, enabling systematic discovery of small molecules that target RNA. Founded in 2018 and headquartered in Cambridge, United States, Rgenta has raised $90M in Series A funding from investors including Boehringer Ingelheim Venture Fund, AstraZeneca, Matrix Partners China, Lilly Asia Ventures, Vivo Capital, Kaitai Capital, Korea Investment Partners, and EQT. The company's approach opens new therapeutic possibilities by targeting previously undruggable RNA structures, expanding the druggable genome beyond protein targets.
Business model
Oncology > Drugs > Diversified,
Neurology > Drugs > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.